DOW JONES23,241.45+587.59 2.59%
S&P 5002,722.88+63.47 2.39%
NASDAQ8,033.27+146.01 1.85%

Deutsche Bank Upgrades Blueprint Medicines to Buy, Announces $70 Price Target

Deutsche Bank analyst Konstantinos N. Aprilakis upgrades Blueprint Medicines (NASDAQ:BPMC) from Hold to Buy and announces $70 price target.

Benzinga · 03/17/2020 15:29

Deutsche Bank analyst Konstantinos N. Aprilakis upgrades Blueprint Medicines (NASDAQ:BPMC) from Hold to Buy and announces $70 price target.